2018 Global Antibody Drug Conjugates Market Forecasts to 2023: Rising Global Cancer Epidemics is Driving the Market


(MENAFNEditorial) DUBLIN, Feb. 21, 2018 /PRNewswire/ --

The report has been added to ResearchAndMarkets.com's offering.

The Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023.

The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.

Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Market Dynamics

Drivers

  • Rising Global Cancer Epidemics
  • Advances in Linking Technologies Re-Instills Hope in ADC
  • Efforts towards Patent Protection to Drive ADC Market
  • Increasing Demand for Antibody Drug Conjugates
  • Challenges

  • Production Hurdles and Cost
  • Inadequacy of Experienced Manufacturers
  • Regulatory Challenges
  • Key Topics Covered:

    1. Research View

    2. Research Methodology

    3. Antibody Drug Conjugate (ADC) - An Introduction

    4. Global Antibody Drug Conjugates Market Outlook to 2023

    5. Commercialized Antibody Drug Conjugates

    6. Antibody Drug Conjugates Pipeline Analysis

    7. Drivers and Challenges

    8. Major Potential Antibody Drug Conjugates in Pipeline

    9. Trends and Developments

    10. Strategic Alliances in the Global Antibody Drug Conjugates Industry

    11. Competitive Assessment

  • Bayer AG
  • Concortis Biotherapeutics
  • F. Hoffman-La Roche Ltd.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • NBE-Therapeutics
  • Oxford BioTherapeutics
  • Pfizer Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • For more information about this report visit

    Media Contact:

    Research and Markets
    Laura Wood, Senior Manager


    For E.S.T Office Hours Call +1-917-300-0470
    For U.S./CAN Toll Free Call +1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900

    U.S. Fax: 646-607-1907
    Fax (outside U.S.): +353-1-481-1716

    View original content:

    SOURCE Research and Markets

    MENAFN2102201800701241ID1096493837


    Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.